SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilBigKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 9/25/2017 4:00:26 AM - Followers: 718 - Board type: Free - Posts Today: 3

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Notice of Effectiveness (effect) 09/22/2017 06:02:17 AM
IPIX News: Securities Registration Statement (simplified Form) (s-3) 09/11/2017 12:47:10 PM
IPIX News: Annual Report (10-k) 09/11/2017 06:04:38 AM
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 09/11/2017 06:04:37 AM
IPIX News: Statement of Changes in Beneficial Ownership (4) 09/06/2017 06:27:18 PM
PostSubject
#197995  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents sox040713 09/24/17 05:24:48 PM
#197146  Sticky Note 4th Quarter catalysts approaching BooDog 09/16/17 07:09:34 AM
#196731  Sticky Note I sent this artilce to Leo,.... looks like cabel 09/14/17 08:36:29 AM
#196630  Sticky Note Proof of Concept (PoC) studies -- the exact slcimmuno 09/13/17 12:06:33 PM
#191428  Sticky Note $IPIX - Innovation Pharmaceuticals Stock May Be A LilBigKahuna 07/23/17 12:25:32 AM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#198019   I don't think Phase 3 would be completed, sox040713 09/25/17 03:40:19 AM
#198018   Even if PASI 75 was 20% including all djs7 09/25/17 12:24:28 AM
#198017   My guess is IPIX will resume talking to sox040713 09/24/17 11:36:20 PM
#198016   Sox, do you have a guess on when Rdunn88 09/24/17 11:10:18 PM
#198015   The pretend CEO can easily explain his reasons Rdunn88 09/24/17 11:02:06 PM
#198014   Your thoughts are pre-emptive. djs7 09/24/17 10:51:58 PM
#198013   How can you say he did the right Rdunn88 09/24/17 10:45:25 PM
#198012   Again, Leo assumed partnerships would be had to Rdunn88 09/24/17 10:30:39 PM
#198011   B-OM P2 Topline results release October 30, my Matagordaville 09/24/17 10:26:17 PM
#198010   "Leo has stated again and again that they nerby 09/24/17 10:23:26 PM
#198009   LilBigKuhuna: Your post below is completely WRONG georgejjl 09/24/17 10:20:09 PM
#198008   What you keep posting assumes uses that are LilBigKahuna 09/24/17 10:12:14 PM
#198007   Are you joking? Antibiotics are worth but a Jhawker 09/24/17 10:11:50 PM
#198006   Why Prurisol is worth at least $10 Billion!!! georgejjl 09/24/17 08:53:22 PM
#198005   We don’t need approval in 2017 or 2018 LilBigKahuna 09/24/17 08:38:18 PM
#198003   But in the meantime we and Ipix know nerby 09/24/17 07:57:19 PM
#198002   Leo didn't waste three years on ABSSSI. He sox040713 09/24/17 06:38:19 PM
#198001   Leveraging the Benefits of the 505(b)(2) Drug Development Approach georgejjl 09/24/17 06:35:17 PM
#197999   Very possible. But without accelerated approval, I'm scottsmith 09/24/17 06:20:48 PM
#197998   Expect both Prurisol for plaque psoriasis and Brilacidin georgejjl 09/24/17 06:13:10 PM
#197997   Leo's frugality enabled IPIX to run eight trials sox040713 09/24/17 06:07:12 PM
#197996   If B-OM top-line result is similar to interim sox040713 09/24/17 05:55:46 PM
#197995   IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents sox040713 09/24/17 05:24:48 PM
#197994   Perhaps B could be used to coat sutures? Very F1ash 09/24/17 04:50:49 PM
#197992   At what dilution were those funds available. He groton68 09/24/17 03:51:30 PM
#197990   I think they could finish a B-OM ph-3 Pepperchino 09/24/17 03:41:58 PM
#197989   Leo didn't have limited funds? Aspire has Rdunn88 09/24/17 03:28:11 PM
#197988   KarinCA approval for any Brilacidin indication will trigger aculeus 09/24/17 03:13:08 PM
#197987   You need to spend money to make money. scottsmith 09/24/17 02:50:57 PM
#197986   Then you would be complaining about the obscene groton68 09/24/17 02:45:24 PM
#197985   You are correct of course. It noretreat 09/24/17 02:42:58 PM
#197984   Nope -- scottsmith is correct. I've been scottsmith 09/24/17 02:40:24 PM
#197983   I'm willing to have my mind changed. scottsmith 09/24/17 02:36:44 PM
#197982   Stop already. Outright false. Leo had limited funds groton68 09/24/17 02:34:42 PM
#197981   I think 2nd half of 2018 can be Pepperchino 09/24/17 02:22:42 PM
#197980   we already know if b-om is as good untohim 09/24/17 02:20:42 PM
#197979   Exactly -- why Leo blundered not running absssi scottsmith 09/24/17 02:12:20 PM
#197978   Time will tell. Was that before the KarinCA 09/24/17 02:12:03 PM
#197977   KarinCA approval for any Brilacidin indication runninggirl2016 09/24/17 02:03:19 PM
#197976   Thx and agree Karin. I just hope Leo Pepperchino 09/24/17 01:51:46 PM
#197975   No. Can we just have one collective 'no' untohim 09/24/17 01:06:04 PM
#197974   I'll paint a picture: IPIX - Developing DaubersUP 09/24/17 01:04:21 PM
#197973   I agree completely georgejjl 09/24/17 12:47:57 PM
#197972   I suspect this is why the most recent KarinCA 09/24/17 12:07:58 PM
#197970   Any news this week? snayeman 09/24/17 10:51:11 AM
#197969   Both groton68 09/24/17 09:31:05 AM
#197968   It’s both. Those weren’t free shares because he LilBigKahuna 09/24/17 09:20:32 AM
#197967   In your prior post you said Aruda didn't scottsmith 09/24/17 08:50:01 AM
#197966   Interesting theory. Do you base that on something? frrol 09/24/17 08:49:23 AM
#197965   To support the thought that Leo needs to Pepperchino 09/24/17 08:38:26 AM
PostSubject